FXIII-Inhibitors

Tridegin


(rec. produced in E. coli, gene derived from Haementeria ghilianii)

Order
Quantity
Price
Status
200 µg 480 € available


Documents
Art. No. T087
Synonym His6-Tridegin
Background info Tridegin is a potent and highly specific inhibitor of human blood coagulation factor XIIIa that has been isolated from Haementeria ghilianii (Finney et al.,1997).
T087 is a recombinant variant of Tridegin containing a carboxyterminal hexahistidine-tag.
Molecular Weight 7.5 kDa
Source Recombinantly produced in E. coli
Purity > 95% [by SDS-PAGE]
Appearance White lyophilized solid
Reagents Recombinant Tridegin is lyophilized from 20 mM Tris-HCl pH 8.0, 50 mM NaCl, 1 mM EDTA, 10 mg/ml sucrose
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots. Keep cooled on ice for short term storage.
Storage Storage for several months is possible at ≤ - 20°C.
Delivery is possible at ambient temperature
Reference(s) Böhm et al., J. Med. Chem. 2014, 57:10355-65
Finney et al., Biochem. J. 1997, 324:797-805
Wallis et al., Blood Coagul. Fibrinolysis. 1997, 8:291-5
Seale et al., Thromb. Haemost. 1997, 77:959-63
Note Intended for research use only, not for use in human, therapeutic or diagnostic applications.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification

Blog  

  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering

Events  

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA

  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy